Peginterferon Alfa-2
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HIV/HCV Coinfection
Conditions
HIV/HCV Coinfection
Trial Timeline
Mar 1, 2005 → Jun 1, 2009
NCT ID
NCT02762383About Peginterferon Alfa-2
Peginterferon Alfa-2 is a phase 3 stage product being developed by Roche for HIV/HCV Coinfection. The current trial status is terminated. This product is registered under clinical trial identifier NCT02762383. Target conditions include HIV/HCV Coinfection.
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02762383 | Phase 3 | Terminated |